VIZIMPRO (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell...
NEW YORK--(BUSINESS WIRE)--Apr 3, 2019--Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO (dacomitinib), a tyrosine kinase inhibitor (TKI),…
